Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Sep;12(3):349–353. doi: 10.1111/j.1365-2125.1981.tb01225.x

Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.

S Rasmussen, P E Nielsen
PMCID: PMC1401812  PMID: 7295465

Abstract

1 In a single blind study seventeen patients with mild or moderate essential hypertension and normal renal function were treated with labetalol alone in increasing doses from 300 via 600 to 1200 mg daily. 2 Average supine BP (systolic/diastolic) was reduced by 24/19 mm Hg. Seven patients attained a diastolic BP less than or equal to Hg. A significant postural fall in systolic BP was recorded, but no symptomatic orthostatic hypotension occurred. 3 In twelve patients measurements of plasma volume (125I-albumin), extracellular volume (82Br-space) and glomerular filtration rate (51Cr-EDTA clearance) on placebo and subsequently labetalol showed no systemic changes. 4 Side effects were few causing two withdrawals because of impotence and arthralgia. 5 It is concluded that monotherapy with labetalol results in clinically relevant, persistent and dose dependent reduction in BP in patients with mild or moderate essential hypertension, apparently without concomitant expansion of body fluid volumes or influence on glomerular filtration rate.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer J. H., Brooks C. S. The long-term effect of propranolol therapy on renal function. Am J Med. 1979 Mar;66(3):405–410. doi: 10.1016/0002-9343(79)91059-3. [DOI] [PubMed] [Google Scholar]
  2. Binder C., Leth A. The distribution volume of 82Br- as a measurement of the extracellular fluid volume in normal persons. Scand J Clin Lab Invest. 1970 May;25(3):291–297. doi: 10.3109/00365517009046208. [DOI] [PubMed] [Google Scholar]
  3. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs. 1978 Apr;15(4):251–270. doi: 10.2165/00003495-197815040-00002. [DOI] [PubMed] [Google Scholar]
  4. Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest. 1972 Nov;30(3):271–274. doi: 10.3109/00365517209084290. [DOI] [PubMed] [Google Scholar]
  5. Dawson A., Johnson B. F., Smith I. K., Munro-Faure A. D. A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol. 1979 Aug;8(2):149–154. doi: 10.1111/j.1365-2125.1979.tb05813.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dustan H. P., Tarazi R. C., Bravo E. L. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med. 1972 Apr 20;286(16):861–866. doi: 10.1056/NEJM197204202861603. [DOI] [PubMed] [Google Scholar]
  7. Finnerty F. A., Jr, Davidov M., Mroczek W. J., Gavrilovich L. Influence of extracellular fluid volume on response to antihypertensive drugs. Circ Res. 1970 Jul;27(1 Suppl 1):71–82. [PubMed] [Google Scholar]
  8. Frick M. H., Pörsti P. Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension. Br Med J. 1976 May 1;1(6017):1046–1048. doi: 10.1136/bmj.1.6017.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Geyskes G. G., Boer P., Vos J., Leenen F. H., Mees E. J. Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. Circ Res. 1975 Jun;36(6 Suppl 1):248–256. doi: 10.1161/01.res.36.6.248. [DOI] [PubMed] [Google Scholar]
  10. Ibsen H., Rasmussen K., Jensen H. A., Leth A. Changes in glomerular filtration rate during long term treatment with propranolol and peripheral vasodilators in patients with arterial hypertension. Dan Med Bull. 1979 Oct;26(6):308–311. [PubMed] [Google Scholar]
  11. Ibsen H., Sederberg-Olsen P. Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin Sci. 1973 Feb;44(2):129–134. doi: 10.1042/cs0440129. [DOI] [PubMed] [Google Scholar]
  12. Kane J., Gregg I., Stephens M. D. A long-term study of labetalol in general practice. Br J Clin Pharmacol. 1979;8(Suppl 2):167S–170S. [PMC free article] [PubMed] [Google Scholar]
  13. Koshy M. C., Mickley D., Bourgiognie J., Blaufox M. D. Physiologic evaluation of a new antihypertensive agent: prazosin HCl. Circulation. 1977 Mar;55(3):533–537. doi: 10.1161/01.cir.55.3.533. [DOI] [PubMed] [Google Scholar]
  14. Parving H. P., Gyntelberg F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res. 1973 May;32(5):643–651. doi: 10.1161/01.res.32.5.643. [DOI] [PubMed] [Google Scholar]
  15. Prichard B. N., Boakes A. J., Hernández R. Long-term treatment of hypertension with labetalol. Br J Clin Pharmacol. 1979;8(Suppl 2):171S–177S. [PMC free article] [PubMed] [Google Scholar]
  16. Pugsley D. J., Nassim M., Armstrong B. K., Beilin L. A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension. Br J Clin Pharmacol. 1979 Jan;7(1):63–68. doi: 10.1111/j.1365-2125.1979.tb00898.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rasmussen S., Rasmussen K. Influence of metoprolol, alone and in combination with a thiazide diuretic, on blood pressure, plasma volume, extracellular volume and glomerular filtration rate in essential hypertension. Eur J Clin Pharmacol. 1979 Jun 12;15(5):305–310. doi: 10.1007/BF00558432. [DOI] [PubMed] [Google Scholar]
  18. Ronnov-Jessen V., Hansen J. Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide. Acta Med Scand. 1969 Oct;186(4):255–263. doi: 10.1111/j.0954-6820.1969.tb01474.x. [DOI] [PubMed] [Google Scholar]
  19. Sanders G. L., Routledge P. A., Rao J. G., Gales G. M., Davies D. M., Rawlins M. D. Labetalol, a cross-over double blind controlled trial. Eur J Clin Pharmacol. 1978 Dec 18;14(5):301–304. doi: 10.1007/BF00611897. [DOI] [PubMed] [Google Scholar]
  20. Sederberg-Olsen P., Ibsen H. Plasma volume and extracellular fluid volume during long-term treatment with propranolol in essential hypertension. Clin Sci. 1972 Aug;43(2):165–170. doi: 10.1042/cs0430165. [DOI] [PubMed] [Google Scholar]
  21. Thompson F. D., Joekes A. M., Hussein M. M. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol. 1979;8(Suppl 2):129S–133S. [PMC free article] [PubMed] [Google Scholar]
  22. Weidmann P., De Chătel R., Ziegler W. H., Flammer J., Reubi F. Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion. Am J Cardiol. 1978 Mar;41(3):570–576. doi: 10.1016/0002-9149(78)90017-6. [DOI] [PubMed] [Google Scholar]
  23. Weil J. V., Chidsey C. A. Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation. 1968 Jan;37(1):54–61. doi: 10.1161/01.cir.37.1.54. [DOI] [PubMed] [Google Scholar]
  24. Williams J. G., De Voss K., Craswell P. W. Labetalol in the treatment of hypertensive renal patients. Med J Aust. 1978 Feb 25;1(4):225–228. doi: 10.5694/j.1326-5377.1978.tb107854.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES